Peter Nicholas Kao
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Peter Nicholas Kao’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G67731 · Current
Licensed to practise in California · since 1989 · expires 2027-05-31 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$22,377
Medicare paid this office $22,377 for 174 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 143 | $15,951 | $81 |
| Return visit (30+ min) | 27 | $3,334 | $104 |
| New patient visit (45+ min) | 22 | $2,274 | $103 |
Who their Medicare patients are
174 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 17% · Women 64% · Also on Medicaid 18% · Health risk score 1.93. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 64% · COPD 63% · Coronary heart disease 33% · Atrial fibrillation 25% · Chronic kidney disease 23% · Diabetes 22% · Heart failure 21% · Cancer 20% · Depression 20% · Stroke 10%.
The office billed $57,510, Medicare allowed $30,893 and paid $22,377; for 262 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 174 | 262 | 76 | 1.93 | $57,510 | $22,377 |
| 2023 | 174 | 252 | 74 | 1.75 | $50,818 | $21,592 |
| 2022 | 170 | 273 | 73 | 1.68 | $58,781 | $22,413 |
| 2021 | 156 | 257 | 74 | 1.78 | $61,829 | $22,393 |
| 2020 | 143 | 255 | 75 | 2.20 | $73,541 | $17,665 |
| 2019 | 136 | 240 | 73 | 2.27 | $22,632 | $15,212 |
| 2018 | 122 | 270 | 73 | 1.95 | $22,364 | $15,206 |
| 2017 | 123 | 264 | 74 | 1.92 | $32,339 | $13,726 |
| 2016 | 108 | 224 | 75 | 1.97 | $28,270 | $10,428 |
| 2015 | 116 | 252 | 74 | 1.97 | $38,279 | $12,544 |
| 2014 | 113 | 269 | 74 | 1.71 | $42,840 | $14,022 |
| 2013 | 118 | 292 | 72 | 1.80 | $50,493 | $16,131 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 144 | $17,677 | $86 |
| New patient visit (45+ min) | 20 | $1,964 | $98 |
2022: 3 services
| Return visit (30+ min) | 144 | $16,776 | $77 |
| New patient visit (45+ min) | 36 | $4,212 | $117 |
| Short return visit (20+ min) | 12 | $701 | $54 |
2021: 3 services
| Return visit (30+ min) | 128 | $17,938 | $87 |
| New patient visit (45+ min) | 20 | $2,425 | $121 |
| Short return visit (20+ min) | 24 | $1,657 | $66 |
2020: 4 services
| Return visit (30+ min) | 113 | $12,823 | $69 |
| New patient visit (45+ min) | 16 | $1,953 | $122 |
| Short return visit (20+ min) | 23 | $1,055 | $41 |
| Return visit (30+ min) | 11 | $811 | $62 |
2019: 3 services
| Return visit (30+ min) | 93 | $10,720 | $66 |
| New patient visit (45+ min) | 19 | $1,947 | $102 |
| Short return visit (20+ min) | 45 | $1,906 | $37 |
2018: 3 services
| Return visit (30+ min) | 59 | $6,562 | $66 |
| Short return visit (20+ min) | 84 | $5,671 | $41 |
| New patient visit (45+ min) | 23 | $2,525 | $110 |
2017: 4 services
| Short return visit (20+ min) | 95 | $6,973 | $41 |
| Return visit (30+ min) | 39 | $3,797 | $70 |
| New patient visit (45+ min) | 18 | $1,873 | $104 |
| New patient visit (30+ min) | 11 | $631 | $57 |
2016: 3 services
| Short return visit (20+ min) | 85 | $6,306 | $41 |
| Return visit (30+ min) | 21 | $1,935 | $60 |
| New patient visit (45+ min) | 13 | $1,269 | $98 |
2015: 3 services
| Short return visit (20+ min) | 93 | $6,875 | $40 |
| Return visit (30+ min) | 41 | $3,300 | $60 |
| New patient visit (45+ min) | 19 | $2,068 | $109 |
2014: 2 services
| Return visit (30+ min) | 63 | $6,787 | $61 |
| Short return visit (20+ min) | 78 | $5,657 | $42 |
2013: 3 services
| Return visit (30+ min) | 65 | $9,500 | $65 |
| Short return visit (20+ min) | 69 | $4,215 | $41 |
| New patient visit (30+ min) | 34 | $2,044 | $60 |
Drugs they prescribed that Part D paid
$434,209
Pharmacies billed $434,209 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 789) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
485 generic and fewer than 11 brand-name prescriptions · $434,209 in drug cost · 74 antibiotic prescriptions to 37 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Adempas | 12 | $165,725 | $13,810 |
| Trelegy Ellipta | 74 | $58,183 | $786 |
| Zileuton Er | 13 | $36,758 | $2,828 |
| Anoro Ellipta | 43 | $26,914 | $626 |
| Breo Ellipta | 15 | $11,481 | $765 |
See all 21 drugs
| Adempas | 12 | $165,725 | $13,810 |
| Trelegy Ellipta | 74 | $58,183 | $786 |
| Zileuton Er | 13 | $36,758 | $2,828 |
| Anoro Ellipta | 43 | $26,914 | $626 |
| Breo Ellipta | 15 | $11,481 | $765 |
| Sildenafil Citrate | 34 | $10,671 | $314 |
| Advair Hfa | 11 | $3,193 | $290 |
| Itraconazole | 16 | $2,734 | $171 |
| Mycophenolate Mofetil | 20 | $1,824 | $91 |
| Fluticasone Propionate Hfa | 12 | $1,781 | $148 |
| Ventolin Hfa | 19 | $1,552 | $82 |
| Fluticasone-Salmeterol | 11 | $1,523 | $138 |
| Azithromycin | 56 | $1,417 | $25 |
| Ethambutol | 18 | $1,260 | $70 |
| Albuterol Sulfate Hfa | 41 | $1,159 | $28 |
| Prednisone | 118 | $916 | $8 |
| Montelukast | 21 | $270 | $13 |
| Omeprazole | 18 | $268 | $15 |
| Simvastatin | 18 | $252 | $14 |
| Furosemide | 33 | $234 | $7 |
| Paxlovid | 11 | $0 | $0 |
Year by year
| 2024 | 789 | 117 | 0% (0) | None | $434,209 |
| 2023 | 744 | 111 | 0% (0) | 31% | $482,685 |
| 2022 | 800 | 115 | 0% (0) | 31% | $474,873 |
| 2021 | 708 | 85 | 0% (0) | 41% | $471,575 |
| 2020 | 692 | 75 | 0% (0) | 39% | $583,818 |
| 2019 | 750 | 80 | 0% (0) | 42% | $696,187 |
| 2018 | 798 | 74 | None | 39% | $605,833 |
| 2017 | 796 | 74 | 0% (0) | 39% | $599,811 |
| 2016 | 772 | 72 | None | 41% | $434,169 |
| 2015 | 808 | 77 | None | 36% | $291,539 |
| 2014 | 776 | 77 | None | 39% | $270,464 |
| 2013 | 584 | 74 | 0% (0) | 39% | $248,168 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Adempas | 12 | $165,382 | $13,782 |
| Zileuton Er | 29 | $92,676 | $3,196 |
| Trelegy Ellipta | 18 | $23,338 | $1,297 |
| Anoro Ellipta | 34 | $20,248 | $596 |
| Sildenafil Citrate | 50 | $17,081 | $342 |
| Spiriva Handihaler | 13 | $14,026 | $1,079 |
| Advair Diskus | 21 | $9,302 | $443 |
| Eliquis | 14 | $8,152 | $582 |
| Ventolin Hfa | 31 | $1,884 | $61 |
| Mycophenolate Mofetil | 16 | $1,786 | $112 |
| Ethambutol | 17 | $1,403 | $83 |
| Azithromycin | 56 | $1,212 | $22 |
| Rifampin | 14 | $1,208 | $86 |
| Albuterol Sulfate Hfa | 27 | $940 | $35 |
| Prednisone | 107 | $909 | $8 |
| Duloxetine | 11 | $427 | $39 |
| Omeprazole | 23 | $409 | $18 |
| Montelukast | 23 | $303 | $13 |
| Paxlovid (Eua) | 26 | $247 | $9 |
| Furosemide | 37 | $208 | $6 |
| Simvastatin | 18 | $200 | $11 |
2022: 21 drugs
| Adempas | 13 | $165,174 | $12,706 |
| Zileuton Er | 40 | $120,200 | $3,005 |
| Anoro Ellipta | 53 | $29,151 | $550 |
| Trelegy Ellipta | 28 | $18,988 | $678 |
| Spiriva Handihaler | 14 | $12,816 | $915 |
| Sildenafil Citrate | 42 | $11,543 | $275 |
| Eliquis | 14 | $7,939 | $567 |
| Wixela Inhub | 19 | $5,991 | $315 |
| Mycophenolate Mofetil | 29 | $2,501 | $86 |
| Albuterol Sulfate Hfa | 48 | $1,903 | $40 |
| Ventolin Hfa | 25 | $1,514 | $61 |
| Azithromycin | 47 | $1,445 | $31 |
| Prednisone | 114 | $1,069 | $9 |
| Itraconazole | 11 | $868 | $79 |
| Rifampin | 14 | $661 | $47 |
| Montelukast | 22 | $617 | $28 |
| Furosemide | 48 | $257 | $5 |
| Duloxetine | 13 | $192 | $15 |
| Simvastatin | 22 | $184 | $8 |
| Paxlovid (Eua) | 17 | $170 | $10 |
| Carvedilol | 16 | $141 | $9 |
2021: 20 drugs
| Adempas | 12 | $143,843 | $11,987 |
| Zileuton Er | 34 | $111,431 | $3,277 |
| Spiriva | 36 | $24,002 | $667 |
| Advair Diskus | 27 | $17,846 | $661 |
| Symbicort | 24 | $17,022 | $709 |
| Anoro Ellipta | 25 | $16,144 | $646 |
| Eliquis | 18 | $15,759 | $876 |
| Flovent Diskus | 28 | $9,415 | $336 |
| Breo Ellipta | 11 | $6,330 | $575 |
| Sildenafil Citrate | 44 | $5,655 | $129 |
| Wixela Inhub | 13 | $2,846 | $219 |
| Itraconazole | 16 | $2,091 | $131 |
| Ventolin Hfa | 28 | $1,625 | $58 |
| Albuterol Sulfate Hfa | 22 | $1,245 | $57 |
| Prednisone | 110 | $968 | $9 |
| Montelukast | 25 | $585 | $23 |
| Ipratropium | 12 | $426 | $35 |
| Carvedilol | 22 | $284 | $13 |
| Furosemide | 42 | $247 | $6 |
| Simvastatin | 20 | $194 | $10 |
2020: 20 drugs
| Adempas | 27 | $308,879 | $11,440 |
| Zileuton Er | 41 | $127,440 | $3,108 |
| Sildenafil Citrate | 38 | $28,227 | $743 |
| Spiriva | 29 | $16,344 | $564 |
| Anoro Ellipta | 19 | $11,944 | $629 |
| Advair Diskus | 15 | $11,145 | $743 |
| Eliquis | 12 | $9,689 | $807 |
| Symbicort | 25 | $8,989 | $360 |
| Flovent Diskus | 23 | $8,094 | $352 |
| Itraconazole | 24 | $6,527 | $272 |
| Flovent Hfa | 16 | $5,443 | $340 |
| Wixela Inhub | 13 | $3,022 | $232 |
| Albuterol Sulfate Hfa | 18 | $1,215 | $67 |
| Ventolin Hfa | 15 | $865 | $58 |
| Prednisone | 102 | $822 | $8 |
| Montelukast | 37 | $681 | $18 |
| Carvedilol | 30 | $412 | $14 |
| Simvastatin | 23 | $212 | $9 |
| Furosemide | 30 | $149 | $5 |
| Lisinopril | 13 | $44 | $3 |
2019: 19 drugs
| Adempas | 34 | $366,499 | $10,779 |
| Zileuton Er | 50 | $143,184 | $2,864 |
| Sildenafil Citrate | 63 | $33,835 | $537 |
| Spiriva | 45 | $29,315 | $651 |
| Advair Diskus | 27 | $16,850 | $624 |
| Flovent Diskus | 30 | $9,222 | $307 |
| Anoro Ellipta | 13 | $7,304 | $562 |
| Spiriva Respimat | 13 | $5,972 | $459 |
| Wixela Inhub | 17 | $4,077 | $240 |
| Duloxetine | 20 | $2,188 | $109 |
| Ventolin Hfa | 27 | $1,556 | $58 |
| Itraconazole | 12 | $1,086 | $91 |
| Prednisone | 89 | $939 | $11 |
| Azithromycin | 19 | $850 | $45 |
| Montelukast | 32 | $520 | $16 |
| Simvastatin | 23 | $272 | $12 |
| Furosemide | 31 | $167 | $5 |
| Carvedilol | 13 | $164 | $13 |
| Metoprolol | 12 | $89 | $7 |
2018: 22 drugs
| Adempas | 26 | $266,623 | $10,255 |
| Zileuton Er | 34 | $90,010 | $2,647 |
| Zyflo Cr | 17 | $79,022 | $4,648 |
| Zyflo | 18 | $52,978 | $2,943 |
| Sildenafil | 79 | $21,299 | $270 |
| Advair Diskus | 31 | $20,301 | $655 |
| Spiriva | 35 | $19,485 | $557 |
| Flovent Diskus | 42 | $9,926 | $236 |
| Anoro Ellipta | 15 | $7,842 | $523 |
| Flovent Hfa | 17 | $6,220 | $366 |
| Itraconazole | 12 | $2,660 | $222 |
| Duloxetine | 22 | $2,046 | $93 |
| Ventolin Hfa | 27 | $1,496 | $55 |
| Azithromycin | 18 | $853 | $47 |
| Prednisone | 102 | $771 | $8 |
| Isosorbide Dinitrate | 14 | $735 | $53 |
| Montelukast | 23 | $331 | $14 |
| Carvedilol | 32 | $300 | $9 |
| Simvastatin | 24 | $245 | $10 |
| Fluticasone Propionate | 13 | $189 | $15 |
| Furosemide | 32 | $168 | $5 |
| Metoprolol | 11 | $113 | $10 |
2017: 18 drugs
| Adempas | 32 | $287,803 | $8,994 |
| Zyflo Cr | 25 | $103,630 | $4,145 |
| Zyflo | 19 | $48,806 | $2,569 |
| Zileuton Er | 18 | $41,287 | $2,294 |
| Sildenafil | 118 | $38,115 | $323 |
| Advair Diskus | 30 | $19,401 | $647 |
| Spiriva | 25 | $17,173 | $687 |
| Flovent Diskus | 49 | $12,237 | $250 |
| Flovent Hfa | 26 | $6,945 | $267 |
| Itraconazole | 17 | $6,182 | $364 |
| Enoxaparin | 15 | $2,691 | $179 |
| Ventolin Hfa | 21 | $1,127 | $54 |
| Duloxetine | 21 | $846 | $40 |
| Prednisone | 73 | $710 | $10 |
| Carvedilol | 37 | $339 | $9 |
| Montelukast | 26 | $327 | $13 |
| Simvastatin | 21 | $267 | $13 |
| Furosemide | 44 | $219 | $5 |
2016: 17 drugs
| Zyflo Cr | 55 | $200,975 | $3,654 |
| Zyflo | 22 | $54,946 | $2,498 |
| Sildenafil | 170 | $43,046 | $253 |
| Advair Diskus | 27 | $16,664 | $617 |
| Spiriva | 27 | $16,447 | $609 |
| Itraconazole | 23 | $11,436 | $497 |
| Flovent Diskus | 32 | $7,169 | $224 |
| Flovent Hfa | 24 | $5,859 | $244 |
| Spiriva Respimat | 11 | $3,714 | $338 |
| Ventolin Hfa | 21 | $1,102 | $52 |
| Carvedilol | 57 | $660 | $12 |
| Prednisone | 40 | $443 | $11 |
| Simvastatin | 30 | $305 | $10 |
| Omeprazole | 14 | $283 | $20 |
| Montelukast | 19 | $248 | $13 |
| Furosemide | 43 | $194 | $5 |
| Losartan | 16 | $188 | $12 |
2015: 20 drugs
| Zyflo Cr | 33 | $131,074 | $3,972 |
| Sildenafil | 149 | $40,943 | $275 |
| Zyflo | 18 | $29,544 | $1,641 |
| Spiriva | 46 | $24,474 | $532 |
| Advair Diskus | 29 | $15,276 | $527 |
| Flovent Diskus | 37 | $7,222 | $195 |
| Flovent Hfa | 17 | $4,647 | $273 |
| Duloxetine | 19 | $1,858 | $98 |
| Ventolin Hfa | 23 | $1,114 | $48 |
| Prednisone | 66 | $771 | $12 |
| Proair Hfa | 13 | $715 | $55 |
| Carvedilol | 60 | $542 | $9 |
| Simvastatin | 25 | $298 | $12 |
| Montelukast | 17 | $187 | $11 |
| Furosemide | 37 | $171 | $5 |
| Fluticasone Propionate | 11 | $149 | $14 |
| Losartan | 11 | $137 | $12 |
| Lisinopril | 13 | $117 | $9 |
| Levofloxacin | 14 | $103 | $7 |
| Ciprofloxacin | 11 | $66 | $6 |
2014: 19 drugs
| Zyflo Cr | 64 | $137,730 | $2,152 |
| Sildenafil | 112 | $38,512 | $344 |
| Spiriva | 58 | $23,765 | $410 |
| Advair Diskus | 29 | $13,983 | $482 |
| Zyflo | 13 | $8,215 | $632 |
| Flovent Diskus | 32 | $5,095 | $159 |
| Flovent Hfa | 14 | $3,362 | $240 |
| Duloxetine | 12 | $3,245 | $270 |
| Ventolin Hfa | 19 | $843 | $44 |
| Proair Hfa | 15 | $735 | $49 |
| Potassium Chloride | 11 | $683 | $62 |
| Prednisone | 57 | $617 | $11 |
| Carvedilol | 70 | $590 | $8 |
| Digox | 13 | $578 | $44 |
| Torsemide | 16 | $450 | $28 |
| Omeprazole | 21 | $370 | $18 |
| Simvastatin | 34 | $323 | $9 |
| Losartan | 12 | $222 | $19 |
| Furosemide | 21 | $103 | $5 |
2013: 12 drugs
| Sildenafil | 60 | $79,266 | $1,321 |
| Zyflo Cr | 37 | $75,897 | $2,051 |
| Advair Diskus | 34 | $15,065 | $443 |
| Spiriva | 28 | $11,595 | $414 |
| Flovent Diskus | 18 | $2,554 | $142 |
| Azithromycin | 16 | $1,773 | $111 |
| Ventolin Hfa | 26 | $1,102 | $42 |
| Simvastatin | 52 | $674 | $13 |
| Prednisone | 57 | $393 | $7 |
| Carvedilol | 16 | $146 | $9 |
| Lisinopril | 17 | $103 | $6 |
| Furosemide | 17 | $91 | $5 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568504686
- Licence
- CA G67731California G67731: Current · expires 2027-05-31
- Trained
- Columbia University College of Physicians and Surgeons, 1988
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G677310
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-13
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.